Why the study?
Interindividual susceptibility to anthracycline-induced cardiotoxicity varies widely, and genetic contributions may be essential for designing individualized preventive approaches.
Do genetic factors influence susceptibility to anthracycline-induced cardiotoxicity in pediatric cancer patients?
Do genetic factors influence susceptibility to anthracycline-induced cardiotoxicity in pediatric cancer patients?
Genetic variants may play an essential role in interindividual susceptibility to anthracycline-induced cardiotoxicity, highlighting the potential for individualized preventive approaches in pediatric cancer patients.
Answers are grounded in this paper and cite their sources.
Genetic screening remains investigational in pediatric oncology; leaves open prospective validation of risk-guided anthracycline strategies.
The wide variation in interindividual susceptibility to anthracycline-induced cardiotoxicity, along with a multitude of genetic variants detected through association studies, suggests that genetic contributions could be essential for the design of new individualized preventive approaches.
No takes yet. Share an insight, caveat, or question.
Petrykey et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: